within Pharmacolibrary.Drugs.N_NervousSystem.N06B_PsychostimulantsAgentsUsedForAdhdAndNootropics.N06BX21_Temgicoluril;

model Temgicoluril
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.7,
    Cl = 4.1666666666666667e-07,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.038,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008333333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Temgicoluril</td></tr><tr><td>ATC code:</td><td>N06BX21</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>38</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Temgicoluril is an anxiolytic agent known for its tranquilizing effects and is primarily used for the treatment of anxiety, stress-related disorders, and sometimes sleep disturbances. It is not approved by the FDA or EMA and is used mainly in some post-Soviet countries, notably in Russia and Ukraine. The drug is often used as a non-benzodiazepine anxiolytic.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic parameters were found in peer-reviewed publications or reputable pharmacological sources for any population. The following parameters are estimated based on general drug class and physicochemical analogs.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N06BX21 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Temgicoluril;
